[go: up one dir, main page]

PE20110001A1 - Derivados de taxanos como agentes citotoxicos - Google Patents

Derivados de taxanos como agentes citotoxicos

Info

Publication number
PE20110001A1
PE20110001A1 PE2010000952A PE2010000952A PE20110001A1 PE 20110001 A1 PE20110001 A1 PE 20110001A1 PE 2010000952 A PE2010000952 A PE 2010000952A PE 2010000952 A PE2010000952 A PE 2010000952A PE 20110001 A1 PE20110001 A1 PE 20110001A1
Authority
PE
Peru
Prior art keywords
taxans
connector
tienyl
fab
refers
Prior art date
Application number
PE2010000952A
Other languages
English (en)
Inventor
Michael L Miller
Ravi V J Chari
Erkan Baloglu
Alain Commercon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PE20110001A1 publication Critical patent/PE20110001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE TAXANOS DE FORMULA (I) DONDE Z ES UN RADICAL DE FORMULA (II), EN DONDE R1 ES UN CONECTOR, T-BUTOXI O TIENILO; R3 ES UN CONECTOR, ISOBUTENILO, TIENILO O FURILO; R4 ES UN CONECTOR, H, HIDROXI, ALCOXI(C1-C4), ENTRE OTROS; R5 O R7 SON CADA UNO H; R6 ES H; R8 ES 2,5-DIMETOXIFENILO, FURILO O TIENILO; R7 O R5 Y R SE ENLAZAN FORMANDO UN ETER CICLICO. SE REFIERE TAMBIEN A UN AGENTE CITOTOXICO QUE COMPRENDE UNO O MAS TAXANOS ENLAZADOS COVALENTEMENTE CON UN AGENTE DE UNION A LA CELULA A TRAVES DE UN GRUPO ENLAZANTE, EN DONDE EL GRUPO ENLAZANTE CONTIENE GRUPOS DISULFURO, TIOETER, ACIDOS LABILES, ENTRE OTROS; Y EL AGENTE DE UNION A LA CELULA ES UN FRAGMENTO DE ANTICUERPO TAL COMO sFV, Fab, Fab' O F(ab')2. DICHOS AGENTES SON UTILES EN LA ELIMINACION DE CELULAS TUMORALES PARTICULARMENTE DE TUMORES SOLIDOS.
PE2010000952A 2004-12-07 2005-11-29 Derivados de taxanos como agentes citotoxicos PE20110001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04292898A EP1669358A1 (en) 2004-12-07 2004-12-07 Cytotoxic agents comprising new taxanes

Publications (1)

Publication Number Publication Date
PE20110001A1 true PE20110001A1 (es) 2011-01-21

Family

ID=34931583

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2010000952A PE20110001A1 (es) 2004-12-07 2005-11-29 Derivados de taxanos como agentes citotoxicos
PE2005001385A PE20061060A1 (es) 2004-12-07 2005-11-29 Derivados de taxanos como agentes citotoxicos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2005001385A PE20061060A1 (es) 2004-12-07 2005-11-29 Derivados de taxanos como agentes citotoxicos

Country Status (22)

Country Link
US (1) US7667054B2 (es)
EP (2) EP1669358A1 (es)
JP (1) JP2008523019A (es)
KR (1) KR20070085781A (es)
CN (1) CN101094857A (es)
AR (1) AR054100A1 (es)
AU (1) AU2005313444B2 (es)
BR (1) BRPI0518869A2 (es)
CA (1) CA2588587A1 (es)
DO (1) DOP2005000248A (es)
EA (1) EA012625B1 (es)
IL (1) IL183404A0 (es)
MA (1) MA29103B1 (es)
MX (1) MX2007006765A (es)
MY (1) MY144632A (es)
NO (1) NO20073033L (es)
NZ (1) NZ555406A (es)
PE (2) PE20110001A1 (es)
TW (1) TW200637836A (es)
UY (1) UY29249A1 (es)
WO (1) WO2006061258A2 (es)
ZA (1) ZA200704790B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
ES2609094T3 (es) * 2007-01-25 2017-04-18 Dana-Farber Cancer Institute, Inc. Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
JP5618549B2 (ja) * 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
MX2010001757A (es) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Anticuerpo monoclonal 175 que activa el receptor egf y derivados y usos del mismo.
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
UY32913A (es) 2009-10-02 2011-04-29 Sanofi Aventis Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero
CN101851231A (zh) * 2010-05-27 2010-10-06 东北林业大学 一种多西紫杉醇新衍生物的合成方法及其在制备抗肿瘤药物中的应用
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
ES2939836T3 (es) 2012-07-12 2023-04-27 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
FI3122757T3 (fi) 2014-02-28 2023-10-10 Hangzhou Dac Biotech Co Ltd Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
CN104693156A (zh) * 2014-10-22 2015-06-10 上海大学 9,10-二羟基-1-去氧紫杉醇类似物及其制备方法
EP4678240A2 (en) 2015-07-12 2026-01-14 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
MX2019005583A (es) 2016-11-14 2019-10-21 Hangzhou Dac Biotech Co Ltd Vinculantes de conjugacion, conjugados de molecula de union a celulas que contienen los vinculantes, metodos de creacion y usos de dichos conjugados con los vinculantes.
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
EP1242401B1 (en) * 1999-11-24 2006-12-27 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
JP2005539009A (ja) * 2002-08-02 2005-12-22 イミュノジェン・インコーポレーテッド 新規の効力のあるタキサンを含む細胞毒性物質、および、それらの治療用途

Also Published As

Publication number Publication date
CA2588587A1 (en) 2006-06-15
UY29249A1 (es) 2006-06-30
EP1669358A1 (en) 2006-06-14
DOP2005000248A (es) 2007-02-15
MA29103B1 (fr) 2007-12-03
EA012625B1 (ru) 2009-10-30
ZA200704790B (en) 2008-08-27
EP1824858A2 (en) 2007-08-29
BRPI0518869A2 (pt) 2008-12-16
KR20070085781A (ko) 2007-08-27
US20060178427A1 (en) 2006-08-10
NO20073033L (no) 2007-08-28
IL183404A0 (en) 2007-10-31
WO2006061258A3 (en) 2006-09-28
NZ555406A (en) 2011-02-25
CN101094857A (zh) 2007-12-26
EA200701251A1 (ru) 2007-12-28
AU2005313444B2 (en) 2011-11-10
WO2006061258A2 (en) 2006-06-15
MY144632A (en) 2011-10-14
JP2008523019A (ja) 2008-07-03
MX2007006765A (es) 2007-08-16
PE20061060A1 (es) 2006-11-14
TW200637836A (en) 2006-11-01
US7667054B2 (en) 2010-02-23
AR054100A1 (es) 2007-06-06
AU2005313444A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
PE20110001A1 (es) Derivados de taxanos como agentes citotoxicos
BRPI0410748B8 (pt) compostos de maitansinóides, suas composições farmacêuticas, métodos de esterificação de maitansinóides, bem como métodos para a sua produção, e conjugado de maitansinóide-agente de ligação celular
DE3885317D1 (de) Makromolekulare Platin-Antitumorverbindungen.
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
ATE516047T1 (de) Ovr110-antikörperzusammensetzungen und anwendungsverfahren
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
ATE500844T1 (de) Detektion der mcsp-oberflächenexpression einer zelle
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
ATE369425T1 (de) Antikörper gegen eine lar-phosphatase untereinheit
TR200200588T2 (tr) N-pirazol A2A reseptör agonistleri
BR0015224A (pt) Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado
BRPI0608175A2 (pt) método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
ES8405071A1 (es) Un procedimiento de preparacion de conjugados inmunoenzimaticos.
ATE69817T1 (de) Tetraoxodiazabicyclo-(3,3,1)-nonane.
CY1105788T1 (el) Χρηση του taci σαν παραγοντα καταπολεμησης ογκων
Hansch et al. The correlation of localization rates of benzeneboronic acids in brain and tumor tissue with substituent constants
CL2024001450A1 (es) Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este
PE20211497A1 (es) Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso
WO2021081457A3 (en) Methods and agents for enhancing t cell therapies
TW200730532A (en) Camptothecin derivatives as chemoradiosensitizing agents
ES2191784T3 (es) Vacunas de tumores de citocinas paracrinas alogenicas.
ATE527998T1 (de) Illudin-analoga als krebsmittel

Legal Events

Date Code Title Description
FC Refusal